Literature DB >> 15272408

Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus.

Mark L Quinlivan1, Anne A Gershon, Sharon P Steinberg, Judith Breuer.   

Abstract

Vaccination against chickenpox causes a varicella-like rash in up to 5% of healthy children and 50% of children with leukemia. The vaccine may establish latency and reactivate to cause herpes zoster, albeit more rarely than wild-type virus. All vaccine preparations are composed of a mixture of varicella-zoster virus strains that show genotypic variation at several loci. We have shown, by DNA sequencing of 40 polymorphic loci, that viruses sampled from vesicles in varicella-like and herpes zoster rashes are single clones. This finding suggests that, between the time of inoculation of the vaccine and development of rash, selection of single strains occurs. The results have general implications for the pathogenesis of varicella-zoster virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15272408     DOI: 10.1086/423210

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Stable and consistent genetic profile of Oka varicella vaccine virus is not linked with appearance of infrequent breakthrough cases postvaccination.

Authors:  Ventzislav Vassilev
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

2.  Varicella-zoster vaccine virus: evolution in action.

Authors:  Jeffrey I Cohen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-21       Impact factor: 11.205

3.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

4.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

5.  Population diversity in batches of the varicella Oka vaccine.

Authors:  R K Kanda; M L Quinlivan; A A Gershon; R A Nichols; J Breuer
Journal:  Vaccine       Date:  2011-02-22       Impact factor: 3.641

6.  Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Authors:  Mark L Quinlivan; Anne A Gershon; Mahmoud M Al Bassam; Sharon P Steinberg; Philip LaRussa; Richard A Nichols; Judith Breuer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

7.  COMMENTARY: Significantly less anti-gC antibody detectable in sera collected after varicella vaccination than after the disease varicella.

Authors:  Charles Grose; Young Juhn
Journal:  Pediatr Infect Dis J       Date:  2012-11       Impact factor: 2.129

8.  Variability of immediate-early gene 62 in german varicella-zoster virus wild-type strains.

Authors:  A Sauerbrei; K Bohn; R Zell; P Wutzler
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

Review 9.  Impact of varicella vaccine on varicella-zoster virus dynamics.

Authors:  D Scott Schmid; Aisha O Jumaan
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

10.  A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.

Authors:  Ruth Harbecke; Michael N Oxman; Beth A Arnold; Charlotte Ip; Gary R Johnson; Myron J Levin; Lawrence D Gelb; Kenneth E Schmader; Stephen E Straus; Hui Wang; Peter F Wright; Constance T Pachucki; Anne A Gershon; Robert D Arbeit; Larry E Davis; Michael S Simberkoff; Adriana Weinberg; Heather M Williams; Carol Cheney; Luba Petrukhin; Katalin G Abraham; Alan Shaw; Susan Manoff; Joseph M Antonello; Tina Green; Yue Wang; Charles Tan; Paul M Keller
Journal:  J Med Virol       Date:  2009-07       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.